Patriot Financial Group Insurance Agency LLC Decreases Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Patriot Financial Group Insurance Agency LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,512 shares of the medical research company’s stock after selling 109 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Charles River Laboratories International were worth $279,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. State Street Corp raised its position in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Charles River Laboratories International by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock valued at $101,483,000 after buying an additional 32,311 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $161.68 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1-year low of $159.65 and a 1-year high of $275.00. The firm has a market capitalization of $8.27 billion, a P/E ratio of 20.24, a P/E/G ratio of 5.94 and a beta of 1.38. The business’s 50-day simple moving average is $185.35 and its 200-day simple moving average is $196.24.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the firm posted $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent research reports. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. The Goldman Sachs Group cut their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus price target of $204.38.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).